{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091494","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.976750+00:00","generated_at":"2026-06-11T11:48:50.032732+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"NRX Pharmaceuticals enters $2M at-the-market equity offering with H.C. Wainwright","bullets":["At-the-market offering of up to $2,000,000 of common stock; sales at market prices via Nasdaq.","H.C. Wainwright will receive 3.0% commission on gross proceeds plus expense reimbursement.","Sales are made under an effective shelf registration statement (S-3) filed June 2022.","Company is not obligated to sell any shares; agreement terminates upon full sale or earlier termination.","Customary reps, warranties, indemnification, and conditions apply to the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091494","json":"https://secwatch.observer/filing/0001104659-23-091494.json","markdown":"https://secwatch.observer/filing/0001104659-23-091494.md","text":"https://secwatch.observer/filing/0001104659-23-091494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/0001104659-23-091494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/tm2323641d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:48:50.032732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a68b41460fdab99895d7153b31966044b424d236","claim":"NRX Pharmaceuticals, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $2,000,000 (effective 2023-08-14).","evidence_excerpt":"On August 14, 2023, NRX Pharmaceuticals, Inc. (the “Company”), entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2,000,000 (the “Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/0001104659-23-091494-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"up to $2,000,000"},{"label":"Effective","value":"2023-08-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}